In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including small cell lung cancer, that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is...
Read More
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including multiple myeloma (MM), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is...
Read More
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including non-Hodgkin lymphoma (NHL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial...
Read More
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including breast cancer, that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....
Read More
In a nutshell This trial looked at the long-term effectiveness and safety of ixazomib (Ixa; Ninlaro) in combination with lenalidomide (R; Revlimid), and dexamethasone (d; Decadron) for the treatment of relapsed/refractory (RR) multiple myeloma (MM). The authors found that there was an improved survival with Ixa-Rd...
Read More
In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was...
Read More
In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was associated...
Read More
In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that adding daratumumab to pomalidomide and dexamethasone regimen reduced the risk of...
Read More
In a nutshell This article looked at the effectiveness and safety of continuous ixazomib (Ninlaro), thalidomide (Thalomid), and dexamethasone (Decadron) (ITd) in the treatment of relapsed and/or refractory (RR) multiple myeloma (MM). The authors found that this regimen was well tolerated and showed promising effectiveness in the treatment of...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of combining pembrolizumab (PEM; Keytruda)) and ipilimumab (IPI; Yervoy) for the treatment of advanced-stage melanoma in patients that have progressed after previous PD-1/L1 therapy. The study concluded that this combination was well tolerated and improved the...
Read More
In a nutshell This study evaluated the safety and effectiveness of lenalidomide (Revlimid) plus rituximab (Rituxan) for patients with diffuse large B-cell lymphoma (DLBCL) that came back or stopped responding to treatment. This study concluded that this treatment showed some effectiveness, but adding other agents may improve outcomes for these...
Read More
In a nutshell The authors compared the safety and effectiveness of pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The study found that pembrolizumab had better survival without cancer worsening compared to BV in these...
Read More
